UBG-T/NK/γδT

N/A

Report date: 2023/08/28 10:22:58

Base Information

Drug NameUBG-T/NK/γδT
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionT lymphocyte replacementsNatural killer cell replacements
TargetsUpdating
Therapy Area/IndicationsLymphoma, Non-HodgkinLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesGuangzhou Bio-Gene Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Bio-Gene Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, Non-HodgkinLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A